Iconovo’s CEO interviewed by DNB Carnegie

Iconovo’s CEO Anders Månsson, was recently interviewed by DNB Carnegie to discuss the company’s latest quarterly report. In the interview, Anders shares his view on Iconovo’s ongoing transition from a platform-focused development company to a more business-driven organisation with increased focus on partnerships and commercial opportunities.

Anders highlights progress in key projects such as ICOres®, ICOpre®, and the inhaled semaglutide programme, as well as the company’s strategy to expand partnerships and strengthen its financial position. He also comments on the ongoing rights issue, with a subscription period running from 13–27 February.

LinkedIn
Email

Related

Anders Månsson at DNB Carnegie Småbolagsdag

Iconovo’s new Interim CEO, Anders Månsson, made his first official appearance for the company when he presented Iconovo at DNB Carnegie’s Småbolagsdag on 27 November.
Read more

Iconovo carries out a directed issue of shares of approx. SEK 25 million and a rights issue of shares of approx. SEK 24.6 million

The Board of Directors of Iconovo AB (“Iconovo” or the “Company”) has today resolved on a directed share issue of approximately SEK 25 million (the “Directed Issue”), and on an issue of shares of approximately SEK 24.6 million with preferential rights for the Company’s existing shareholders (the “Rights Issue”, together the “Issues”).
Read more

Iconovo appoints Anders Månsson as new CEO

Iconovo AB (publ), a leader in the development of inhalable drugs based on proprietary inhalers and dry powder formulations, has today appointed Anders Månsson as interim CEO of Iconovo AB. The Board of Directors has in parallel initiated a process to recruit a permanent CEO, for which Anders also is a candidate.
Read more